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Abstract: The characterization of colon cancer stem cells (CSCs) may help to develop novel diagnostic
and therapeutic procedures. p53 loss increases the pool of CSCs in colorectal cancer (CRC). Recent
reports suggest that the oncostatic effects of melatonin could be related to its ability to kill CSCs.
Although there are no data linking the loss of p53 function and melatonin synthesis or signaling
in cancer, melatonin does activate the p53 tumor-suppressor pathway in this disease. In this work,
we analyze whether the expression of melatonin synthesis and signaling genes are related to the
expression of CSC markers and the implication of p53 status in samples from patients with CRC.
Arylalkylamine N-acetyltransferase (AA-NAT), MT1, and MT2 expression decreased in tumor
samples versus normal mucosa samples in mutated p53 (mtp53) tumors versus those with wild-type
p53 (wtp53). Further, AA-NAT and MT2 expression were lower in advanced stages of the disease
in wtp53 tumors. On the contrary, CD44 and CD66c expression was higher in tumor versus normal
mucosa in wtp53 tumors. Additionally, CD44 expression was higher in advanced stages of the disease
regardless of the p53 status. Patients with CD44highCD66chigh and wtp53 tumors in advanced stages
showed low expression of AA-NAT and MT2 in wtp53 tumors. These results could indicate a possible
interaction of these pathways in CRC.
Keywords: colorectal cancer; melatonin; cancer stem cells; p53; metastasis
1. Introduction
Colorectal cancer is the third most common cancer in men and the second most common in
women, and this disease is a major cause of death worldwide [1]. In the last decade, there have
been important advances in the knowledge of molecular and genetic alterations responsible for the
development of colorectal cancer; however, at present there are only a few predictive biomarkers
available to select patients who would respond better to the currently available high-cost treatments [2].
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According to the most recent concept of carcinogenesis, direct experimental evidences support
the hypothesis that tumors contain a small subpopulation(s) of cancer stem cells (CSCs) which
have self-renewal and tumor initiation capacity. CSCs are also responsible for tumor heterogeneity,
metastasis, resistance to anti-cancer therapies, and relapse [3,4]. CSCs are most commonly identified by
cell surface markers. Colorectal cancer (CRC) stem cells express CD44, CD133, CD166, CD24, CD66c,
CD29, the epithelial cell adhesion molecule, Musashi-1, aldehyde dehydrogenase-1 (ALDH1), and
the leucine-rich-repeat containing G protein-coupled receptor 5 (LGR5) [5,6]. Previous studies have
suggested that genetic alterations or microenvironment influences the appearance of CSC-like cells
genotype [7,8]. The tumor suppressor protein p53 is frequently mutated in many types of human
tumors, including CRC [9]. p53 protein plays a key role in stem cell biology, and regulates stem cell
differentiation and self-renewal, quiescence, and multidrug resistance [10]. Recent studies on the
direct and indirect links between CSCs and p53 have further solidified the importance of therapeutic
targeting of p53 in CSCs. However, the mechanisms by which p53 regulates CSCs in CRC are poorly
understood [11].
Melatonin, the major product of the pineal gland, is synthesized from tryptophan under
the control of the enzymes arylalkylamine N-acetyltransferase (AA-NAT) and N-Acetylserotonin
O-methyltransferase (ASMT) [12]. The presence of melatonin has also been detected in multiple
extrapineal tissues in which melatonin-synthesizing enzymes have been identified [13]. Some of its
functions are mediated through membrane (MT1 and MT2) or nuclear receptors (RZR/RORa) [14–16].
Melatonin also has other receptor-independent functions such as antioxidant and free radical
scavenging [17,18]. Recently, the regulation of viability, proliferation, and differentiation of stem
cells (SC) by melatonin has been proposed [19,20].
Melatonin plays an important role in cancer by inhibiting tumor growth and metastasis through
different pathways, depending on the type of cancer studied and the dose of melatonin used [12].
In CRC, melatonin inhibits cell growth and induces apoptosis in vitro [21–23] and in vivo [24]. Recently,
it has been reported that melatonin decreases CSCs and dysplastic injuries in colon tissue [24]. To date,
there are no data linking loss of p53 function and melatonin synthesis or signaling in cancer, however
some findings emphasize that activation of the p53 tumor-suppressor pathway, mediated by MT1
and MT2, may be a critical mediator in the anticancer activity of melatonin in CRC and breast cancer
in vitro [25,26].
Previous data from our research team showed a decreased in MT1, MT2, and AA-NAT expression
in CRC related to gender and invasion grade of tumors [27,28]. Herein, we investigate whether those
expression decreases in melatonin synthesis and signaling genes are related to the expression of CSC
markers in CRC and the implication of p53 status.
2. Results
2.1. Evaluation of Arylalkylamine N-acetyltransferase (AA-NAT), MT1, and MT2 Expression in Samples from
Human colorectal cancer(CRC) with Different Status of p53
p53 sequencing analysis was successful in all 183 specimens. p53 mutations were detected in
76 patients (42%). Mutations are characterized in Table S1. The frequency of p53 mutations was
different between tumor stages (stage I + stage II, and stage III + stage IV; p = 0.025) being higher in
advanced stages of the disease (Table 1). That frequency was almost significant when considering
the tumor differentiation grade (differentiated, moderately differentiated, and poorly differentiated;
p = 0.095) but no differences were found between the anatomic location of the tumor (proximal, distal,
rectal; p = 0.437).
Next, we evaluated the expression of AA-NAT, MT1, and MT2 in our cohort of patients. In all
patients, the expression in tumor samples versus normal mucosa was less than one for AA-NAT, MT1,
and MT2 (0.39 ± 0.06, 0.31 ± 0.03, and 0.36 ± 0.05, respectively), which indicates that their expression
decreased in tumor samples versus normal mucosa, as reported elsewhere [27–29]. Considering the
p53 status, the expression of AA-NAT, MT1, and MT2 was lower in patients with mutant p53 (mtp53)
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than in patients with wild-type p53 (wtp53) (p < 0.05, p < 0.01, and p < 0.05, respectively) (Figure 1A).
Protein expression of AA-NAT, MT1, and MT2 was higher in normal mucosa than in tumor samples in
wtp53 tumors and weakly detected in mtp53 tumors (Figure 1B).
Table 1. Prognostic covariates.
Covariates TP53 a Wild-Type % (n) TP53 Mutant % (n) p b
Gender
Male 62.0 (66) 63.2 (48) 0.893
Female 38.0 (41) 36.8 (28)
Differentiation Grade
Well differentiated 16.8 (18) 35.5 (27) 0.095
Moderately differentiated 69.1 (74) 51.3 (39)
Poorly differentiated 14 (15) 13.2 (10)
Stage
Stage I + II (Early) 59.8 (64) 33.3 (32) 0.025
Stage III + IV (Advanced) 40.2 (43) 57.9 (44)
Location
Proximal 47.7 (51) 38.2 (29) 0.437
Distal 47.7 (51) 56.6 (43)
Rectal 4.6 (5) 5.2 (4)
a P53 gene; b Significant associations are shown in bold (p < 0.05).
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Figure 1. (A) mRNA expression of arylalkylamine N-acetyltransferase (AA-NAT), MT1, and MT2 in 
all patients, patients with wtp53 tumors and patients with mtp53 tumors. Data represent mean ± 
S.E.M. * p < 0.05 versus wtp53; ** p < 0.01 versus wtp53; (B) Protein expression of AA-NAT, MT1, and 
MT2 in normal (N) and malignant (T) colon samples in four patients with wtp53 and four patients 
with mtp53 tumors. 
When stratifying by tumor stage and p53 status, the expression of AA-NAT decreased 
significantly (p < 0.05) in advanced versus early stage tumors (Figure 2A), whereas the expression of 
MT1 and MT2 did not change in all patients (Figure 2B,C). In wtp53 tumors, differences in AA-NAT 
(p < 0.05) and MT2 expression levels (p < 0.05) were found between early and advanced tumors 
(Figure 2A,B). However, no significant changes in AA-NAT, MT1, and MT2 expression levels were 
found between early stage tumors and advanced ones in mtp53 samples (Figure 2). When 
comparing the gene expression at the same tumor stage, significant decreases in AA-NAT, MT1, and 
MT2 expression levels were found in early stage mtp53 tumors versus early stage wtp53 tumors (p < 
0.05) (Figure 2A–C). 
Figure 1. (A) mRNA expression of arylalkylamine N-acetyltransferase (AA-NAT), MT1, and MT2 in all
patients, patients with wtp53 tumors and patients with mtp53 tumors. Data represent mean ± S.E.M.
* p < 0.05 versus wtp53; ** p < 0.01 versus wtp53; (B) Protein expression of AA-NAT, MT1, and MT2
in normal (N) and malignant (T) colon samples in four patients with wtp53 and four patients with
mtp53 tumors.
When stratifying by tumor stage and p53 status, the expression of AA-NAT decreased significantly
(p < 0.05) in advanced versus early stage tumors (Figure 2A), whereas the expression of MT1 and MT2
did not change in all patients (Figure 2B,C). In wtp53 tumors, differences in AA-NAT (p < 0.05) and MT2
expression levels (p < 0.05) were found between early and advanced tumors (Figure 2A,B). However,
no significant changes in AA-NAT, MT1, and MT2 expression levels were found between early stage
tumors and advanced ones in mtp53 samples (Figure 2). When comparing the gene expression at the
same tumor stage, significant decreases in AA-NAT, MT1, and MT2 expression levels were found in
early stage mtp53 tumors versus early stage wtp53 tumors (p < 0.05) (Figure 2A–C).
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Table 2. Relationship between cancer stem cell CSC markers and melatonin synthesis and signaling
genes according to p53 status and progression of the disease.
p53 Wild-Type
Gene











ns 0.045Low 7 (63.6) 17 (89.5) 4 (40.0) 16 (80.0)
High 4 (36.4) 2 (10.5) 6 (60.0) 4(20.0)
MT1
ns nsLow 11 (91.7) 19 (95.0) 7 (77.8) 18 (90.0)
High 1 (8.3) 1 (5.0) 2 (22.2) 2 (10)
MT2 b
nsLow 8 (66.7) 17 (85.0) 4 (44.4) 20 (100.0)
High 4 (33.3) 3 (15.0) 5 (55.6) 0 (0.0)
p53 Mutated
Gene











ns nsLow 6 (75.0) 4 (80.0) 4 (40.0) 10 (83.3)
High 2 (25.0) 1 (20.0) 6 (60.0) 2 (16.7)
MT1
ns nsLow 9 (100.0) 5 (71.4) 7 (77.8) 11 (100.0)
High 0 (0.0) 2 (28.6) 2 (22.2) 0 (0.0)
MT2 b
ns nsLow 7 (77.8) 6 (85.7) 6 (66.7) 9 (81.8)
High 2 (22.2) 1 (14.3) 3 (33.3) 2 (18.2)
a Bivariate analysis: p calculated by χ2 test or Fisher’s test; b Mantel–Haenszel test: p ≤ 0.01.
3. Discussion
At present, CSCs-based therapy represents a major challenge for the development of a novel
generation of drugs and effective treatments in CRC, and other types of cancer. However, the
mechanisms that regulate CSC renewal and carcinogenesis are not clear [32].
Very recent reports suggested that the oncostatic effects of melatonin could be related to its cytotoxicity
induced in CSCs of the brain [33,34], glioblastoma [35], and breast tumors [36]. In CRC, melatonin
reduced the CSC pool and the dysplastic injuries induced by constant light and carcinogen treatments
in a model of rats [24]. According to this, we found that AA-NAT, MT1, and MT2 negatively correlate to
CD44 and CD66c in CRC. In fact, melatonin regulates key pathways involved in intestinal mesenchymal
and CSC differentiation, such us the Wnt/β-catenine, BMPs, and Notch pathways [19,37–40].
Several studies have delineated the effects of p53 loss and p53 mutation on the CSC pool [11].
Loss of wtp53 function enriches putative colon CSCs, and restoration of wild type p53 in p53-null
HCT116 cells eliminated the putative CSC populations [41]. The combination of 5-fluorouracil plus
p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing
putative colon CSCs [42]. Other studies showed that HMGA1 silencing restores normal stem cells (SC)
characteristics in colon CSCs by increasing p53 levels [43]. It has been recently demonstrated that p53
transcriptionally represses CD44 protein expression in both normal and tumor-derived mammary
epithelial and lung tumor cells [44]. However, loss p53 function is not associated with elevated CD44
expression in CCR [31]. According to this, our results showed higher expression of CD44 in wtp53
than in mtp53 tumors. CD66c expression also decreases in mtp53 tumors versus those bearing wtp53.
Melatonin has been shown to regulate the expression of both p53 and p21 [45] and to increase
p38-mediated p53 phosphorylation in cancer cells and the p53-dependent DNA damage response [26,46]
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trough MT1 and MT2 [25]. A decreased expression of AA-NAT, MT1, and MT2 in CCR mtp53 tumors
was found in our study. Our results are consistent with previously published data from our research
group [27,28], with a lower expression of AA-NAT and MT2 found in advanced rather than in early
stages of the disease. However, this was found in wtp53 tumors but not in mtp53 tumors. These results
indicate that a loss of p53 could lead to decreased expression of AA-NAT and MT2 in CRC, and that
p53 could regulate their expression, or vice versa. In fact, melatonin is a molecule with important
antioxidant properties [17,18] and a decrease in its synthesis and signaling could lead to increased
oxidative stress in the colonic tissue [47], which in turn could produce p53 mutations [48]. Our results
are also consistent with those reported by Nemeth et al., who found decreased expression of the
melatonin receptor 1 in human colorectal adenocarcinomas [29]. Recently, Ziolko et al. also studied
the profile of the melatonin MT1 receptor gene in CRC, and they reported a significant increase in its
levels of expression in cancerous versus non-cancerous tissue [49]. These discrepancies could be due
to the low number of patients included in these two studies (24 and 39, respectively), while our cohort
includes 184 patients.
There is no consensus about the origin of CSCs in CRC. Although, under the CSC hypothesis
the origin of the tumor is not necessarily a SC, this could be the case in the intestine, a tissue where
the differentiated cells are renewed every 2–7 days and whose functional unit, the Lieberkühn crypts,
is underlyed by mesenchymal stem cells (MSCs). Regardless of their origin, CSCs are of considerable
clinical significance, having been shown to be more resistant to radiotherapy and chemotherapy than
other tumor cells. This is a feature shared with normal SCs, which present various strategies to resist
chemotherapy, including cellular quiescence and the expression of proteins capable of eliminating
drugs from the cytoplasm, such as ATP-binding cassette (ABC) transporters and multidrug resistance
(MDR) proteins. [50]. During the process of transformation to CSCs, decreased expressions of genes
related to melatonin synthesis and signaling pathways could take place. The fact that we have found a
negative correlation between AA-NAT, MT1, and MT2 with CD44 and CD66c in advanced stages of
the disease, in our cohort of patients, reinforces this hypothesis, although, more studies are necessary
to confirm it. Further, we found that those correlations are higher in wtp53 tumors, which indicates
that a functional p53 protein is necessary for the interrelation between melatonin-related genes and
CSC markers in CRC to exist.
Personalized medicine involves the use of genetic information about an individual patient to select
or optimize the patient’s preventive and therapeutic care. Despite the success of new treatments, most
patients eventually progress due to the presence of intra- and inter-tumor heterogeneity conferring
resistance. Factors contributing to heterogeneity include the presence of CSC subpopulations, among
others [51]. P53 is a very important factor involved in the development of CSC subpopulations
in CRC [11,41–43]. The presence of p53 mutations induces resistance in cultured CRC cells and is
indicative of poor survival in patients after 5-fluorouracil treatment [52,53], the gold standard in
CRC chemotherapy treatment that, depending on the tumor stage, is combined with other drugs [54].
Melatonin is able to increase the cytotoxicity of 5-fluorouracil in cultured cells and in patients with
advanced (metastatic) CRC [55,56]. Here we show a possible mechanism of this melatonin effect
and the possibility of using it in combination with 5-fluorouracil in patients with mtp53 resistant to
treatment with 5-fu alone. The five-transmembrane glycoprotein CD133 is one of the first colon CSC
markers identified [57] and its use as a CSC marker has been controversial since then [58]. The selection
of colon cancer cells based on the positivity for AC133, an epitope on the CD133 protein, allows for the
identification of tumorigenic and clonogenic cell populations [59]. On the other hand, CD133+ as well
as CD133− metastatic colon cancer cells were shown to be able to form new tumors and their expression
does not seem to be restricted to the stem cell compartment, which indicates that use of CD133 as a CSC
marker is questionable [60–62]. Since colon cancer cells sorted for CD44high or CD66chigh displayed
high tumorigenicity [5,6], we used these CSCs markers in our study. CD44highCD66chigh tumors also
correlated with low expression of AA-NAT and MT2 in wtp53 tumors in advanced stages of the
disease, which is indicative of the important role of melatonin and it’s signaling through MT2 in CRC.
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In conclusion, in view of the results from this study, melatonin could be considered a therapeutic
approach in patients with advanced CRC and with tumors bearing wtp53, decreasing, at least in part,
the resistance to commonly used therapies [34]. In the near future, the oncology community will need
to validate this possibility and make certain that patients who are candidates for melatonin therapy
undergo the appropriate testing and treatment.
4. Materials and Methods
4.1. CRC Human Samples
The Andalusian Tumor Bank Network (RBTA) provided the samples used. The Ethics Committee
of San Cecilio University Hospital approved (Ethical Committee of Clinical Research of Granada;
proyect code: PI-067/2013; date of approval: 01/24/2014) the study and all patients gave written
informed consent for the use of samples in biomedical research. All specimens (viable tumor tissues
and adjacent normal tissues) were dissected immediately and fresh-frozen in Tissue-Tek1 (Optimal
Cutting Temperature Compound, Sakura Finetek Europe B.V., Zoeterwoude, The Netherlands) by
standard methods. AA-NAT, MT1, MT2, CD44, CD66c, and Ubiquitin C (UBC) mRNA were evaluated
in the tumor tissue and adjacent normal mucosa of 183 patients (mean age 71 ± 9 years) who underwent
surgery for primary sporadic CCR (Table S2). In relation to the tumor staging (classified according to
TNM nomenclature), the samples were grouped in early (stage I + stage II) and advanced (stage III +
stage IV) stages because no significant results were obtained in each group separately. DNA was also
extracted to evaluate the status of p53.
4.2. RNA Isolation and cDNA Synthesis
Total RNA from tissue samples was prepared using the TRIzol reagent (Invitrogen, Carlsbad, CA,
USA). The amount of total RNA was determined by UV spectrophotometry, and RNA integrity was
assessed by agarose gel electrophoresis. First-strand cDNA was prepared by reverse transcription with
oligo-dT primers from 2 µg of total RNA in 50 µL of total volume using a commercial cDNA synthesis
kit (AccuScriptTM High Fidelity 1st Strand cDNA Synthesis Kit, Stratagene, San Diego, CA, USA).
4.3. Real-Time PCR (RT-PCR)
About 5 µL of the cDNA was amplified for 40 cycles with specific primers for AA-NAT, MT1, MT2,
CD44, CD66c, and UBC (Table S3). PCR reactions containing SYBR-green were performed using the
Mx3000P QPCR System (Stratagene, Austin, TX, USA). UBC was used as housekeeping to normalize
mRNA levels. Standard curves were generated for each target gene by plotting Ct values versus log
cDNA dilution. PCR products were verified by a melting profile and, agarose gel electrophoresis to
rule out nonspecific PCR products and primer dimers.
4.4. DNA Extraction
Genomic DNA was isolated from tissue samples using the QIAamp ADN mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions. The DNA was quantified on a
NanoDrop ND-1000 spectrophotometer (Implen GmbH, Munich, Germany) and analyzed by agarose
electrophoresis. The 260/280 ratios ranged from 1.7 to 2.0, yet gel electrophoresis indicated a generally
acceptable quality for these samples.
4.5. Sequencing of p53 Mutations
The samples were analyzed for TP53 mutations in exons 2–10 by PCR using specific primers
(Table S4). Automated DNA sequencing of PCR products was performed using a 3130XL Genetic
Analyzer and then assessed with Sequence Scanner v1.0 software (Applied Biosystems, Foster City,
CA, USA).
Int. J. Mol. Sci. 2017, 18, 1251 10 of 14
The detected mutations were confirmed by two independent amplifications and reactions.
The IARC p53 database (http://www.p53.iarc.fr/), which describes the activity of each p53 protein
encoded by a single-nucleotide point mutation, was consulted [63]. TP53mutants are considered to
have a median transcriptional activity >75% were classified as wild type for the calculation. A median
transcriptional activity <75% was considered partially functional and was classified as mutant for the
calculation [64].
4.6. Western Blotting
Tissues from patients were homogenized in ice-cold lysis buffer (50 mM Tris-HCl pH 7.4,
150 mM NaCl, 0.1% SDS, 1% Igepal C, 0.5% sodium deoxycholate, 1 mM Na3VO4, 10 mg/mL leupeptin,
2 mg/mL aprotinin, and 1 mg/mL pepstatin, 1 mM PMSF, 10 nM NaF) on ice for 45 min and clarified
by centrifugation at 16,000× g for 2 × 30 min. Fifty micrograms of protein were loaded into 12%
SDS-polyacrylamide gels. Subsequently, the proteins were transferred to PVDF filters and the blots
were probed with appropriate antibodies for MT1 (Santa Cruz Biotechnology, Inc., Dallas, TX, USA),
MT2 (Santa Cruz Biotechnology, Inc.), AA-NAT (Santa Cruz Biotechnology, Inc.), CD44 (Santa Cruz
Biotechnology, Inc), CD66c (Santa Cruz Biotechnology, Inc.), and β-actin (Santa Cruz Biotechnology,
Inc.). Immunoreactivity was assessed on an enhanced electrochemoluminescence autoradiography
system (Amersham Biosciences, Buckinghamshire, UK).
4.7. Statistical Analysis
mRNA levels of genes in tumor tissues were normalized using their levels in normal mucosa
from the same patient and were compared by the paired Student’s t test. Pearson’s correlation was
used to express the results of the correlation analyses. Bivariate analysis was performed using the χ2
test and the Fisher’s exact and Mantel–Haenszel tests. Cut-off value between low and high expression
level was set at the median mRNA expression level for each of the genes analyzed. p values lower
than 0.05 were considered significant. All statistical calculations were performed using SPSS software
version 15.0 for Windows (SPSS Inc., Chicago, IL, USA).
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/6/1251/s1.
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